fluoxetine has been researched along with atomoxetine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, ND; Robertson, DW; Swartzendruber, JK; Wong, DT; Yang, KS | 1 |
| Carlier, PR; Lo, MM; Lo, PC; Reynolds, IJ; Richelson, E; Sharma, TA; Tatsumi, M | 1 |
| Beedle, EE; Bymaster, FP; Findlay, J; Gallagher, PT; Krushinski, JH; Mitchell, S; Robertson, DW; Thompson, DC; Wallace, L; Wong, DT | 1 |
| Ching, B; Fleck, BA; Gao, Y; Gogas, K; Hudson, S; Pontillo, J; Wade, WS; Wu, D | 1 |
| Dwight, W; Eccles, W; Fleck, BA; Genicot, MJ; Gogas, K; Hudson, S; Kiankarimi, M; Mostofi, YS; Wade, WS | 1 |
| Alfinito, P; Bray, J; Cohn, ST; Deecher, DC; Fensome, A; Johnston, G; Koury, E; Mahaney, PE; Marella, MA; McComas, CC; Nogle, L; Trybulski, EJ; Vu, AT; Ye, F; Zhang, P | 1 |
| Bray, J; Deecher, D; Johnston, G; Koury, E; Mahaney, PE; McComas, CC; Terefenko, EA; Trybulski, E; Vu, A; Zhang, P | 1 |
| Childers, SR; Davies, HM; Manning, JR; Sexton, T | 1 |
| Bray, JA; Cohn, ST; Deecher, DC; Dooley, R; Goljer, I; Johnston, GH; Leiter, J; Mahaney, PE; Moore, WJ; Terefenko, EA; Trybulski, EJ; Vu, AT; Zhang, P | 1 |
| Bray, J; Deecher, D; Fensome, A; Harrison, J; Kim, C; Koury, E; Mahaney, PE; Mark, L; McComas, CC; Mugford, CA; Terefenko, EA; Trybulski, EJ; Vu, AT; Whiteside, GT; Zhang, P | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fluoxetine and atomoxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for fluoxetine and atomoxetine
| Article | Year |
|---|---|
Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor.
Topics: Animals; Brain; Fluoxetine; Kinetics; Models, Molecular; Molecular Conformation; Norepinephrine; Propylamines; Rats; Serotonin; Serotonin Antagonists; Synaptosomes; X-Ray Diffraction | 1988 |
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
Topics: Amino Alcohols; Animals; Antidepressive Agents; Dopamine; Humans; Neurotransmitter Uptake Inhibitors; Norepinephrine; Rats; Serotonin; Species Specificity | 1998 |
Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
Topics: Antidepressive Agents; Binding Sites; Clinical Trials as Topic; Depressive Disorder; Duloxetine Hydrochloride; Humans; Kinetics; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Thiophenes | 2003 |
Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).
Topics: Adrenergic Uptake Inhibitors; Amines; Atomoxetine Hydrochloride; Binding Sites; Cell Line; Chemistry, Pharmaceutical; Desipramine; Drug Design; Humans; Inhibitory Concentration 50; Models, Chemical; Molecular Conformation; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Structure-Activity Relationship | 2008 |
Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.
Topics: Atomoxetine Hydrochloride; Chemistry, Pharmaceutical; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Design; Humans; Indenes; Inhibitory Concentration 50; Microsomes, Liver; Models, Chemical; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Serotonin; Structure-Activity Relationship | 2008 |
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
Topics: Humans; Indoles; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism; Structure-Activity Relationship | 2008 |
Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.
Topics: Benzimidazoles; Combinatorial Chemistry Techniques; Drug Design; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism | 2008 |
1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors.
Topics: Amines; Animals; Antidepressive Agents, Second-Generation; Biogenic Monoamines; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Design; Humans; Neurotransmitter Uptake Inhibitors; Protein Binding; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stereoisomerism | 2009 |
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
Topics: Adrenergic Uptake Inhibitors; Animals; Chemistry, Pharmaceutical; Dogs; Dopamine Plasma Membrane Transport Proteins; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Norepinephrine; Propanolamines; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship | 2009 |
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
Topics: Administration, Oral; Animals; Behavior, Animal; Benzimidazoles; Biological Transport; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Hyperalgesia; Male; Neurotransmitter Uptake Inhibitors; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Propanolamines; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Spinal Nerves; Structure-Activity Relationship; Substrate Specificity | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |